CellCarta and Pillar Biosciences entered a strategic partnership to provide NGS-based tumor profiling for oncology clinical trials. The collaboration combines Pillar’s OncoReveal kitted panels with CellCarta’s global lab network and biomarker knowledge base. The firms said the goal is to reduce screening friction and failure rates while improving turnaround times, enabling scalable companion diagnostic program support for clinical trial sponsors. The deal also targets standardized panel implementation across regions, with flexibility for indication-specific or custom panels aligned to sponsor programs. For trial operations, the partnership focuses on practical bottlenecks—sample logistics, turnaround delays, and inconsistent panel adoption—that can slow enrollment and complicate biomarker reporting. While financial terms were not disclosed, the structure suggests both companies view trial biomarker execution as a differentiator, not just a lab service line.